Alternative Realities: Investing in the Future of Healthcare
Season 01 Episode 06 On previous episodes, we’ve discussed the muted return outlook for a traditional 60/40 portfolio and the return-enhancing potential of Private Equity and Venture Capital. As companies wait longer to IPO, investors are turning to pri
November 2, 202425m 24s
Audio is streamed directly from the publisher (episodes.castos.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Season 01 Episode 06
On previous episodes, we’ve discussed the muted return outlook for a traditional 60/40 portfolio and the return-enhancing potential of Private Equity and Venture Capital. As companies wait longer to IPO, investors are turning to private markets for access to the fastest-growing part of a business’s lifecycle. In this episode, we’re going to explore the opportunities in private healthcare and biotechnology. Dr. David Kelly is joined by Gaurav Gupta, Managing Partner of Life Science Private Capital within J.P. Morgan Private Capital. He is a neurosurgeon turned investor, and we’re so excited to have him here to discuss the trends he’s seeing in the market.
On previous episodes, we’ve discussed the muted return outlook for a traditional 60/40 portfolio and the return-enhancing potential of Private Equity and Venture Capital. As companies wait longer to IPO, investors are turning to private markets for access to the fastest-growing part of a business’s lifecycle. In this episode, we’re going to explore the opportunities in private healthcare and biotechnology. Dr. David Kelly is joined by Gaurav Gupta, Managing Partner of Life Science Private Capital within J.P. Morgan Private Capital. He is a neurosurgeon turned investor, and we’re so excited to have him here to discuss the trends he’s seeing in the market.